Sirolimus-FKBP12.6 Impairs Endothelial Barrier Function Through Protein Kinase C-&agr; Activation and Disruption of the p120–Vascular Endothelial Cadherin Interaction

Objective—Sirolimus (SRL) is an immunosuppressant drug used to prevent rejection in organ transplantation and neointimal hyperplasia when delivered from drug-eluting stents. Major side effects of SRL include edema and local collection of intimal lipid deposits at drug-eluting stent sites, suggesting that SRL impairs endothelial barrier function (EBF). The aim of this study was to address the role of SRL on impaired EBF and the potential mechanisms involved. Approach and Results—Cultured human aortic endothelial cells (HAECs) and intact human and mouse endothelium was examined to determine the effect of SRL, which binds FKBP12.6 to inhibit the mammalian target of rapamycin, on EBF. EBF, measured by transendothelial electrical resistance, was impaired in HAECs when treated with SRL or small interfering RNA for FKBP12.6 and reversed when pretreated with ryanodine, a stabilizer of ryanodine receptor 2 intracellular calcium release channels. Intracellular calcium increased in HAECs treated with SRL and normalized with ryanodine pretreatment. SRL-treated HAECs demonstrated increases in protein kinase C-&agr; phosphorylation, a calcium sensitive serine/threonine kinase important in vascular endothelial (VE) cadherin barrier function through its interaction with p120-catenin (p120). Immunostaining of HAECs, human coronary and mouse aortic endothelium treated with SRL showed disruption of p120–VE cadherin interaction treated with SRL. SRL impairment of HAEC EBF was reduced with protein kinase C-&agr; small interfering RNA. Mice treated with SRL demonstrated increased vascular permeability by Evans blue albumin extravasation in the lungs, heart, and aorta. Conclusions—SRL-FKBP12.6 impairs EBF by activation of protein kinase C-&agr; and downstream disruption of the p120–VE cadherin interaction in vascular endothelium. These data suggest this mechanism may be an important contributor of SRL side effects related to impaired EBF.

[1]  S. Yuan,et al.  Myosin Light Chain Kinase Signaling in Endothelial Barrier Dysfunction , 2013, Medicinal research reviews.

[2]  R. Virmani,et al.  Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted mammalian target of rapamycin inhibitors via S6 kinase-dependent inhibition of cell proliferation. , 2013, Journal of the American College of Cardiology.

[3]  S. Elledge,et al.  Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR. , 2013, Cancer research.

[4]  A. Malik,et al.  PKC&agr; Activation of p120-Catenin Serine 879 Phospho-Switch Disassembles VE-Cadherin Junctions and Disrupts Vascular Integrity , 2012, Circulation research.

[5]  Soo-Jin Kang,et al.  In-stent neoatherosclerosis: a final common pathway of late stent failure. , 2012, Journal of the American College of Cardiology.

[6]  L. Martínez-Dolz,et al.  Withdrawal of proliferation signal inhibitors due to adverse events in the maintenance phase of heart transplantation. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  Masataka Nakano,et al.  The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. , 2011, Journal of the American College of Cardiology.

[8]  D. Sabatini,et al.  Mammalian Target of Rapamycin ( mTOR ) Inhibitor for Treatment of Cancer , 2011 .

[9]  G. King,et al.  Activation of protein kinase C isoforms and its impact on diabetic complications. , 2010, Circulation research.

[10]  A. Malik,et al.  Regulation of endothelial permeability via paracellular and transcellular transport pathways. , 2010, Annual review of physiology.

[11]  B. Meier,et al.  Proliferation signal inhibitor-induced decrease of vascular endothelial cadherin expression and increase of endothelial permeability in vitro are prevented by an anti-oxidant. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  L. Martínez-Dolz,et al.  Tolerance profile of the proliferation signal inhibitors everolimus and sirolimus in heart transplantation. , 2008, Transplantation proceedings.

[13]  G. Klintmalm,et al.  Calcineurin inhibitor‐sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity , 2007, Clinical transplantation.

[14]  Gang-yi Wu,et al.  Removal of Fkbp12/12.6 From Endothelial Ryanodine Receptors Leads to an Intracellular Calcium Leak and Endothelial Dysfunction , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[15]  C. Kuperwasser,et al.  Endothelial Akt signaling is rate-limiting for rapamycin inhibition of mouse mammary tumor progression. , 2007, Cancer research.

[16]  Susan L. Hamilton,et al.  FK506 Binding Protein 12/12.6 Depletion Increases Endothelial Nitric Oxide Synthase Threonine 495 Phosphorylation and Blood Pressure , 2007, Hypertension.

[17]  M. Neeman,et al.  Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. , 2006, Cancer cell.

[18]  Y. Hiroi,et al.  Decreased vascular lesion formation in mice with inducible endothelial-specific expression of protein kinase Akt. , 2006, The Journal of clinical investigation.

[19]  A. Malik,et al.  Signaling mechanisms regulating endothelial permeability. , 2006, Physiological reviews.

[20]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[21]  S. P. Srinivas,et al.  Thrombin-induced phosphorylation of the regulatory light chain of myosin II in cultured bovine corneal endothelial cells. , 2004, Experimental eye research.

[22]  P. Vincent,et al.  VE-cadherin-p120 interaction is required for maintenance of endothelial barrier function. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[23]  P. Vincent,et al.  Cellular levels of p120 catenin function as a set point for cadherin expression levels in microvascular endothelial cells , 2003, The Journal of cell biology.

[24]  I. Shiojima,et al.  Role of Akt Signaling in Vascular Homeostasis and Angiogenesis , 2002, Circulation research.

[25]  P Kouklis,et al.  Ca(2+) signalling and PKCalpha activate increased endothelial permeability by disassembly of VE-cadherin junctions. , 2001, The Journal of physiology.

[26]  J. Lankelma,et al.  Simvastatin Improves Disturbed Endothelial Barrier Function , 2000, Circulation.

[27]  R. Morris,et al.  Graft-versus-host disease prevention by rapamycin: cellular mechanisms. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[28]  Wolfgang Ziegler,et al.  Multiple pathways control protein kinase C phosphorylation , 2000, The EMBO journal.

[29]  F. Luft,et al.  Calcium antagonists ameliorate ischemia-induced endothelial cell permeability by inhibiting protein kinase C. , 1999, Circulation.

[30]  Jie Chen,et al.  The FKBP12-Rapamycin-binding Domain Is Required for FKBP12-Rapamycin-associated Protein Kinase Activity and G1 Progression* , 1999, The Journal of Biological Chemistry.

[31]  M. Schreier,et al.  SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. , 1997, Transplantation.

[32]  S. Fleischer,et al.  Selective Binding of FKBP12.6 by the Cardiac Ryanodine Receptor* , 1996, The Journal of Biological Chemistry.

[33]  A. Marks,et al.  Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein , 1994, Cell.

[34]  L A Herzenberg,et al.  Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Malik,et al.  Increased endothelial albumin permeability mediated by protein kinase C activation. , 1990, The Journal of clinical investigation.

[36]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. III. In vitro and in vivo evaluation. , 1978, The Journal of antibiotics.

[37]  S. Sehgal,et al.  Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. , 1975, The Journal of antibiotics.